These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

540 related articles for article (PubMed ID: 24083402)

  • 1. Deferasirox for the treatment of iron overload in non-transfusion-dependent thalassemia.
    Taher AT; Temraz S; Cappellini MD
    Expert Rev Hematol; 2013 Oct; 6(5):495-509. PubMed ID: 24083402
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Deferasirox: a review of its use for chronic iron overload in patients with non-transfusion-dependent thalassaemia.
    Shirley M; Plosker GL
    Drugs; 2014 Jun; 74(9):1017-27. PubMed ID: 24919862
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Profile of deferasirox for the treatment of patients with non-transfusion-dependent thalassemia syndromes.
    Ricchi P; Marsella M
    Drug Des Devel Ther; 2015; 9():6475-82. PubMed ID: 26719673
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Deferasirox reduces iron overload significantly in nontransfusion-dependent thalassemia: 1-year results from a prospective, randomized, double-blind, placebo-controlled study.
    Taher AT; Porter J; Viprakasit V; Kattamis A; Chuncharunee S; Sutcharitchan P; Siritanaratkul N; Galanello R; Karakas Z; Lawniczek T; Ros J; Zhang Y; Habr D; Cappellini MD
    Blood; 2012 Aug; 120(5):970-7. PubMed ID: 22589472
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Deferasirox effectively reduces iron overload in non-transfusion-dependent thalassemia (NTDT) patients: 1-year extension results from the THALASSA study.
    Taher AT; Porter JB; Viprakasit V; Kattamis A; Chuncharunee S; Sutcharitchan P; Siritanaratkul N; Galanello R; Karakas Z; Lawniczek T; Habr D; Ros J; Zhu Z; Cappellini MD
    Ann Hematol; 2013 Nov; 92(11):1485-93. PubMed ID: 23775581
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Approaching low liver iron burden in chelated patients with non-transfusion-dependent thalassemia: the safety profile of deferasirox.
    Taher AT; Porter JB; Viprakasit V; Kattamis A; Chuncharunee S; Sutcharitchan P; Siritanaratkul N; Origa R; Karakas Z; Habr D; Zhu Z; Cappellini MD
    Eur J Haematol; 2014 Jun; 92(6):521-6. PubMed ID: 24460655
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Deferasirox for managing iron overload in people with thalassaemia.
    Meerpohl JJ; Antes G; Rücker G; Fleeman N; Motschall E; Niemeyer CM; Bassler D
    Cochrane Database Syst Rev; 2012 Feb; (2):CD007476. PubMed ID: 22336831
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Deferasirox--an oral agent for chronic iron overload.
    Vanorden HE; Hagemann TM
    Ann Pharmacother; 2006 Jun; 40(6):1110-7. PubMed ID: 16735647
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Deferasirox: pharmacokinetics and clinical experience.
    Galanello R; Campus S; Origa R
    Expert Opin Drug Metab Toxicol; 2012 Jan; 8(1):123-34. PubMed ID: 22176640
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Deferasirox : a review of its use in the management of transfusional chronic iron overload.
    Yang LP; Keam SJ; Keating GM
    Drugs; 2007; 67(15):2211-30. PubMed ID: 17927285
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Deferasirox for the treatment of chronic iron overload in transfusional hemosiderosis.
    Shashaty G; Frankewich R; Chakraborti T; Choudary J; Al-Fayoumi S; Kacuba A; Castillo S; Robie-Suh K; Rieves D; Weiss K; Pazdur R
    Oncology (Williston Park); 2006 Dec; 20(14):1799-1806, 1811; discussion 1811-13, 1817. PubMed ID: 17263129
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Deferasirox for transfusion-related iron overload: a clinical review.
    Lindsey WT; Olin BR
    Clin Ther; 2007 Oct; 29(10):2154-66. PubMed ID: 18042472
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Iron chelation therapy for transfusional iron overload: a swift evolution.
    Musallam KM; Taher AT
    Hemoglobin; 2011; 35(5-6):565-73. PubMed ID: 21910602
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Deferasirox (Exjade) for the treatment of iron overload.
    Cappellini MD; Taher A
    Acta Haematol; 2009; 122(2-3):165-73. PubMed ID: 19907154
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Results from a 1-year, open-label, single arm, multi-center trial evaluating the efficacy and safety of oral Deferasirox in patients diagnosed with low and int-1 risk myelodysplastic syndrome (MDS) and transfusion-dependent iron overload.
    Nolte F; Höchsmann B; Giagounidis A; Lübbert M; Platzbecker U; Haase D; Lück A; Gattermann N; Taupitz M; Baier M; Leismann O; Junkes A; Schumann C; Hofmann WK; Schrezenmeier H
    Ann Hematol; 2013 Jan; 92(2):191-8. PubMed ID: 23073603
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel treatment options for transfusional iron overload in patients with myelodysplastic syndromes.
    Goldberg SL
    Leuk Res; 2007 Dec; 31 Suppl 3():S16-22. PubMed ID: 18037414
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A pharmaco-economic evaluation of deferasirox for treating patients with iron overload caused by transfusion-dependent thalassemia in Taiwan.
    Ho WL; Chung KP; Yang SS; Lu MY; Jou ST; Chang HH; Yang YL; Lin DT; Lin KH
    J Formos Med Assoc; 2013 Apr; 112(4):221-9. PubMed ID: 23537869
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Deferasirox for transfusion-dependent patients with myelodysplastic syndromes: safety, efficacy, and beyond (GIMEMA MDS0306 Trial).
    Angelucci E; Santini V; Di Tucci AA; Quaresmini G; Finelli C; Volpe A; Quarta G; Rivellini F; Sanpaolo G; Cilloni D; Salvi F; Caocci G; Molteni A; Vallisa D; Voso MT; Fenu S; Borin L; Latte G; Alimena G; Storti S; Piciocchi A; Fazi P; Vignetti M; Tura S
    Eur J Haematol; 2014 Jun; 92(6):527-36. PubMed ID: 24580147
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of deferasirox in myelodysplastic syndromes.
    Breccia M; Alimena G
    Ann Hematol; 2013 Jul; 92(7):863-70. PubMed ID: 23417759
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Deferasirox administration for the treatment of non-transfusional iron overload in patients with thalassaemia intermedia.
    Ladis V; Berdousi H; Gotsis E; Kattamis A
    Br J Haematol; 2010 Dec; 151(5):504-8. PubMed ID: 20950401
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.